(Q22241491)

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Diagnostic criteria for the neuropathological assessment of Alzheimer's disease: current status and major issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Disease modifying approaches for Alzheimer's pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

The cerebral beta-amyloid angiopathies: hereditary and sporadic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Apolipoprotein E genotype and neuropathological phenotype in two members of a German family with chromosome 14-linked early onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

A beta oligomers - a decade of discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Polypeptide conjugates comprising a beta-amyloid plaque-specific epitope as new vaccine structures against Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Alzheimer disease and cerebrovascular pathology: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Developing novel immunogens for an effective, safe Alzheimer's disease vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Active immunization of mice with an Abeta-Hsp70 vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Review: modulating factors in amyloid-beta fibril formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Fimbria-fornix lesion does not affect APP levels and amyloid deposition in the hippocampus of APP+PS1 double transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Immunizations in the elderly: do they live up to their promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Active immunization trial in Abeta42-injected P301L tau transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021

Dosing in phase II trial of Alzheimer's vaccine suspended

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021

Effects of epitopes combination and adjuvants on immune responses to anti-Alzheimer disease DNA vaccines in mice

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021

Genetic factors in the genesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021

Alzheimer's disease: genes, proteins, and therapy

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021

Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021

Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021

Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021

Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: complication of diabetes

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021

Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021

Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1535

7 January 2021